Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A
医疗健康 · 专科与仿制药
Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients' health in China. It offers Aikening, an IV fusion inhibitor for dual therapy of HIV-1. The company's pipeline products include FB2004 indicated for HBV; FB7011 and FB7013 for IgA nephropathy; FB7012 to treat hyperuricemia and gout; FB7041 to treat tumors; FB7024 for the treatment of hyperlipidemia; FB7023 to treat ASCVD; FB7033 for the treatment of MASH; FB4001 for osteoporosis; and FB3002 for pain management. Frontier Biotechnologies Inc. was founded in 2002 and is headquartered in Nanjing, China.
MARKET 市值 10.36B CNY PE 2765.0x
52W ¥13.06 – ¥29.98
EODHD · Q 2026-03-31 · 同步 2026-07-12
QUALITY PEG — 营收 YoY 948.9%
▲ ROE 0.3% 营业利润率 76.0% 净利润率 0.9%